The Effects of Exercise in Parkinson's Disease.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson Disease 10
- Sponsor
- Pacific Parkinson's Research Centre
- Enrollment
- 18
- Locations
- 1
- Primary Endpoint
- PET
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Parkinson's disease is caused by a reduction of dopamine causing motor deficits. The investigators are studying how exercise can help PD patients by increasing dopamine release in an area of the brain that coordinates movement, the striatum. The investigators will enroll PD patients into two groups; one group will complete a 12-week aerobic exercise program and the other will complete a 12-week control program including yoga and stretching only. The investigators will measure changes in dopamine release before and after either 12-week intervention. Subjects will complete motor and cognitive questionnaires in addition to functional magnetic resonance imaging and positron emission tomography neuroimaging.
Detailed Description
The purpose of this study is to determine the basis for symptomatic and disease modifying benefits of exercise in Parkinson's disease (PD). Although the benefits of exercise in PD have been purported for several decades, only recently have there been controlled reports of symptomatic benefits in Parkinson's disease in terms of bradykinesia, postural balance and quality of life. There have been unsubstantiated suggestions that exercise may improve cognition and mood in PD. The mechanisms underlying such benefits are poorly understood. Exercise may induce dopamine release, thereby contributing to improved motor function in the dorsal striatum, and to enhanced mood and reduced apathy in the ventral striatum. We will test the hypotheses that exercise results in altered synaptic plasticity in the form of altered connectivity in response to aerobic exercise and reward-induced dopamine release. We will assess networks of functional connectivity using functional magnetic resonance imaging and measure dopamine release with positron emission tomography (PET).
Investigators
A. Jon Stoessl
Director, Pacific Parkinson's Research Centre
Pacific Parkinson's Research Centre
Eligibility Criteria
Inclusion Criteria
- •Idiopathic PD according to UK Brain Bank criteria (modified to permit inclusion of subjects with a family history)
- •Mild to moderate Parkinsonism (Hoehn \& Yahr stages I-III)
Exclusion Criteria
- •General exclusion criteria will include:
- •more than 120 minutes per week of activities \>3 MET or a score exceeding 4 on the "Baseline Exercise Screening Tool" (Appendix, Fig. 1);
- •atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);
- •significant osteoporosis or arthritis;
- •other neurological disease (e.g. myopathy);
- •self-reports claustrophobia;
- •history of cancer within 5 years of study participation;
- •high dose of radiation from other procedures within the year;
- •taking rasagiline or selegiline for PD therapy;
- •not able to tolerate being off PD medication for up to 24 hours;
Outcomes
Primary Outcomes
PET
Time Frame: 3 months
Dopamine release will be assessed using positron emission tomography (PET)
Secondary Outcomes
- fMRI(3 months)